Oppenheimer Maintains Outperform on Apellis Pharmaceuticals, Raises Price Target to $79
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Justin Kim has maintained an Outperform rating on Apellis Pharmaceuticals (NASDAQ:APLS) and increased the price target from $75 to $79.
January 30, 2024 | 2:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Justin Kim reaffirmed an Outperform rating on Apellis Pharmaceuticals and raised the price target to $79, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst like Justin Kim from Oppenheimer typically signals a strong conviction in the company's future performance and growth potential. This can lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100